by The global Nausea Medicine Market is estimated to be valued at US$ 7.52 Bn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Nausea medicine refers to prescription and over-the-counter medications that help relieve symptoms of nausea and vomiting. Some common nausea medicines include antihistamines, anticholinergics, phenothiazines, cannabinoids, 5-HT3 receptor antagonists, and corticosteroids. These medicines work by blocking receptors in the brain that trigger nausea and vomiting. They are effective in treating nausea caused by chemotherapy, surgery, pregnancy, motion sickness, foodborne illnesses, and gastrointestinal disorders. The global nausea medicine market has witnessed significant growth in recent years owing to rising cancer cases and growing adoption of chemotherapy.
Market key trends:
One of the key trends in the nausea medicine market is the introduction of newer drug formulations with extended release and fewer side effects. Companies are focusing on developing more targeted drug delivery systems to maximize drug absorption and minimize systemic exposure. For instance, sublingual and nasal sprays allow for direct absorption into the bloodstream bypassing the gastrointestinal tract. This results in rapid symptom relief. There is also a rise in combination drug therapies where two classes of antiemetics are combined to achieve enhanced efficacy. This has improved treatment outcomes for refractory cases of chemotherapy-induced nausea and vomiting. Growing research into cannabinoid-based therapies for nausea is another trend witnessed in the market.
Porter’s Analysis
Threat of new entrants: Low capital requirements and established brand loyalty reduce threat of new entrants in the nausea medicine market.
Bargaining power of buyers: Large buyer base and generic availability of nausea medicines increases buyers bargaining power.
Bargaining power of suppliers: Established relationships and proprietary technologies reduce suppliers bargaining power.
Threat of new substitutes: Limited threat from substitutes due to unique effectiveness of different nausea medicine classes.
Competitive rivalry: Intense rivalry among major manufacturers to gain higher market share.
Key Takeaways
Global Nausea Medicine Market Demand is expected to witness high growth, exhibiting CAGR of 5.9% over the forecast period, due to increasing prevalence of cancer and chemotherapies. The nausea medicine market size for 2023 is US$ 7.52 Bn.
Regionally, North America dominates the nausea medicine market owing to increasing adoption of novel therapies and growth in pharmaceutical sector. However, Asia Pacific is expected to exhibit fastest growth during the forecast period due to rising healthcare expenditures and developing healthcare infrastructure.
Key players operating in the nausea medicine market are GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bayer AG, Takeda Pharmaceutical Company Limited, AstraZeneca plc, Eli Lilly and Company. GlaxoSmithKline plc leads the market with wide product portfolio and strong distribution network across major markets.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
